The higher burden of KRAS mutation on cfDNA levels has been shown to be negatively correlated with OS.308–310 Furthermore, the ctDNA level is a good indicator of pancreatic cancer progression during or after treatment (chemotherapy and/or surgery). This evidence concerns the gene KRAS and pancreatic neoplasm.